Horizon Pharma Inc. (NASDAQ:HZNP)’s share price traded down 4.2% on Monday . The stock traded as low as $17.68 and last traded at $17.84, with a volume of 4,358,400 shares. The stock had previously closed at $18.62.

Several equities analysts have weighed in on the company. Citigroup Inc. assumed coverage on Horizon Pharma in a research report on Wednesday, June 1st. They set a “neutral” rating for the company. Zacks Investment Research raised Horizon Pharma from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research report on Monday, July 11th. Piper Jaffray Cos. reissued an “overweight” rating and set a $33.00 price target (down previously from $34.00) on shares of Horizon Pharma in a research report on Wednesday, August 10th. Vetr raised Horizon Pharma from a “hold” rating to a “buy” rating and set a $19.82 price target for the company in a research report on Tuesday, June 7th. Finally, Brean Capital reissued a “buy” rating and set a $30.00 price target on shares of Horizon Pharma in a research report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $29.15.

The company’s market cap is $2.87 billion. The company has a 50-day moving average price of $20.32 and a 200 day moving average price of $17.54.

Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.50 by $0.12. During the same quarter last year, the company posted $0.39 EPS. The company had revenue of $257.40 million for the quarter, compared to analyst estimates of $235.43 million. Horizon Pharma’s revenue was up 48.9% on a year-over-year basis. On average, equities analysts expect that Horizon Pharma Inc. will post $2.15 EPS for the current year.

In other news, Director Virinder Nohria sold 25,000 shares of the stock in a transaction on Wednesday, June 15th. The stock was sold at an average price of $17.69, for a total transaction of $442,250.00. Following the completion of the sale, the director now owns 189,836 shares in the company, valued at approximately $3,358,198.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jeffrey W. Sherman sold 2,900 shares of the stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $20.00, for a total value of $58,000.00. The disclosure for this sale can be found here.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.